Chembio Diagnostics is an American point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. It offers products for treatment of malaria, ebola, febrile illness, dengue fever, and influenza, as well as provides human and veterinary diagnostics. Chembio Diagnostics was founded in 1985 and is headquartered in Hauppauge, New York.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Chembio Diagnostics news
01.02.2023
Biosynex is buying Chembio for $17.2 million, or $0.45 per share. Closing of deal is planned in the 1st quarter of the current year.
06.05.2022
The loss of Chembio Diagnostics under GAAP for the 3 months of 2022 was $8.79 million, up 95.3% from $4.5 million in the previous year. Revenue increased 2.2-fold to $18.817 million from $8.724 million a year earlier.
04.03.2022
Chembio Diagnostics' GAAP loss for 2021 was $33.904 million, up 32.8% from $25.521 million the previous year. Revenue increased 47.3% to $47.819 million from $32.47 million a year earlier.
06.12.2021
Chembio Diagnostics has applied to the FDA for approval of the DPP SARS-CoV-2 Antigen testing system. The system analyzes a minimally invasive nasal swab using DPP Micro Reader or DPP Micro Reader 2 optical analyzers, which can detect COVID-19 in 20 minutes.
General information
| Company name | Chembio Diagnostics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
| Business address | 3661 Horseblock Road Medford, NY 11763 United States |
| Mailing address | 3661 Horseblock Road Medford, NY 11763 United States |
| Website | chembio.com |
| Information disclosure | www.sec.gov |
English (US) 